Your browser doesn't support javascript.
loading
Hemodialysis Patients Show a Highly Diminished Antibody Response after COVID-19 mRNA Vaccination Compared to Healthy Controls
Benedikt Simon; Harald Rubey; Andreas Treipl; Martin Gromann; Boris Hemedi; Sonja Zehetmayer; Bernhard Kirsch.
Affiliation
  • Benedikt Simon; LKH Mistelbach
  • Harald Rubey; LK Mistelbach
  • Andreas Treipl; LK Mistelbach
  • Martin Gromann; LK Mistelbach
  • Boris Hemedi; LK Hainburg
  • Sonja Zehetmayer; Medical University of Vienna
  • Bernhard Kirsch; LK Mistelbach
Preprint in English | medRxiv | ID: ppmedrxiv-21254259
ABSTRACT
1.1.1 Background and ObjectivesHemodialysis patients are prone to infection with SARS-COV2 and show a high probability of a severe course of disease and high mortality when infected. In many countries hemodialysis patients are prioritised in vaccination programs to protect this vulnerable community. However, no hemodialysis patients were included in efficacy trials of SARS CoV-2 vaccines and therefore efficacy and safety data for this patient group are lacking. These data would be critical, since hemodialysis patients showed decreased responses against various other vaccines and this could mean decreased response to SARS CoV-2 vaccines. 1.2 Design, setting, participants, and measurementsWe conducted a prospective cohort study consisting of a group of 81 hemodialysis patients and 80 healthy controls who were vaccinated with mRNA vaccine BNT162b2 (BionTech/Pfizer, 2 doses with an interval of 21 days). Anti-SARS-COV-2 S antibody response in all participants was measured 21 days after the second dose. The groups were compared with univariate quantile regressions and a multiple analysis. Adverse events (AEs) of the vaccination were assessed with a standardized questionnaire. We also performed a correlation of HBs-Antibody response with the SARS-COV-2 antibody response in the hemodialysis patients. 1.3 ResultsDialysis patients had significantly lower Anti-SARS-COV-2 S antibody titres than healthy control patients 21 days after vaccination with BNT162b2 (median dialysis Patients 171 U/ml versus median controls 2500 U/ml). Age also had a significant but less pronounced influence on antibody titres. Dialysis patients showed less AEs than the control group. No significant correlation was found for Hepatitis B vaccine antibody response and SARS CoV-2 vaccine antibody response. 1.4 ConclusionsHemodialysis patients exhibit highly diminished SARS-COV-2 S antibody titres compared to a cohort of controls. Therefore these patients could be much less protected by SARS CoV-2 mRNA vaccination than expected. Alternative vaccination schemes must be considered and preventive measures must be maintained after vaccination.
License
cc_no
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Experimental_studies / Observational study / Prognostic study / Rct Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Experimental_studies / Observational study / Prognostic study / Rct Language: English Year: 2021 Document type: Preprint
...